T-Cell Non-Hodgkin Lymphoma — Trials

T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

1,008 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 225
Recruiting: 127
Ph III recruiting: 9
Growth YoY: +23.4%
Industry share: 21%
Top sponsor: Institute of Hematology & Blood Diseases Hospital, China
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (169)

clinicaltrialsPublishedShowing 51–100 of 1,008 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07768943	GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma	not yet recruiting	Phase 2	620	Fudan UniversityOTHER	1	Aug 17, 2026	clinicaltrials
NCT02978625	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	active not recruiting	Phase 2	68	National Cancer Institute (NCI)NIH	1	Aug 13, 2026	clinicaltrials